Byhealth Co., Ltd (SHE:300146)
China · Delayed Price · Currency is CNY 12.31
-0.13 (-1.05%)
At close: Feb 6, 2026
Byhealth Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 5,963 | 6,781 | 9,373 | 7,828 | 7,375 | 6,075 |
Other Revenue | 57.66 | 57.66 | 34.02 | 33.04 | 55.92 | 19.78 |
| 6,020 | 6,838 | 9,407 | 7,861 | 7,431 | 6,095 | |
Revenue Growth (YoY) | -18.18% | -27.30% | 19.66% | 5.79% | 21.93% | 15.83% |
Cost of Revenue | 2,027 | 2,321 | 2,938 | 2,506 | 2,544 | 2,277 |
Gross Profit | 3,993 | 4,518 | 6,468 | 5,356 | 4,887 | 3,818 |
Selling, General & Admin | 2,971 | 3,589 | 4,353 | 3,560 | 2,863 | 2,251 |
Research & Development | 87.62 | 148.63 | 179.33 | 158.5 | 150.3 | 139.95 |
Other Operating Expenses | 55.86 | 38.43 | 91.4 | 74.29 | 72.11 | 66.95 |
Operating Expenses | 3,121 | 3,774 | 4,622 | 3,795 | 3,091 | 2,457 |
Operating Income | 872.17 | 744.04 | 1,847 | 1,561 | 1,797 | 1,361 |
Interest Expense | -15.81 | -12.15 | -4.15 | -2.2 | -10.18 | -23.73 |
Interest & Investment Income | - | 57.73 | 159.89 | 231.76 | 167.18 | 199.57 |
Currency Exchange Gain (Loss) | 5.22 | 5.22 | -5.07 | -1.7 | -4.8 | -6.08 |
Other Non Operating Income (Expenses) | 7.05 | -1 | -4.18 | -2.51 | -2.97 | -23.37 |
EBT Excluding Unusual Items | 868.62 | 793.83 | 1,993 | 1,786 | 1,946 | 1,508 |
Gain (Loss) on Sale of Investments | 10.87 | 4.6 | 51.21 | -177.85 | 69.03 | 258.68 |
Gain (Loss) on Sale of Assets | 44.63 | 14.44 | 0.11 | -3.91 | 0.12 | -0.23 |
Asset Writedown | 4.19 | -4.5 | -1.41 | -8.87 | -1.2 | -1.4 |
Other Unusual Items | 92.23 | 92.23 | 152.9 | 109.12 | 164.32 | 3.89 |
Pretax Income | 1,021 | 900.61 | 2,196 | 1,705 | 2,178 | 1,769 |
Income Tax Expense | 290.56 | 252.75 | 417.18 | 293.53 | 411.7 | 224.59 |
Earnings From Continuing Operations | 729.99 | 647.86 | 1,779 | 1,411 | 1,766 | 1,544 |
Minority Interest in Earnings | -38.47 | 4.97 | -32.44 | -25.41 | -12.32 | -19.84 |
Net Income | 691.53 | 652.83 | 1,746 | 1,386 | 1,754 | 1,524 |
Net Income to Common | 691.53 | 652.83 | 1,746 | 1,386 | 1,754 | 1,524 |
Net Income Growth | -3.12% | -62.62% | 26.01% | -20.99% | 15.07% | - |
Shares Outstanding (Basic) | 1,680 | 1,674 | 1,695 | 1,690 | 1,655 | 1,588 |
Shares Outstanding (Diluted) | 1,725 | 1,718 | 1,695 | 1,711 | 1,670 | 1,588 |
Shares Change (YoY) | 1.46% | 1.33% | -0.91% | 2.42% | 5.21% | 7.07% |
EPS (Basic) | 0.41 | 0.39 | 1.03 | 0.82 | 1.06 | 0.96 |
EPS (Diluted) | 0.40 | 0.38 | 1.03 | 0.81 | 1.05 | 0.96 |
EPS Growth | -4.52% | -63.11% | 27.16% | -22.86% | 9.38% | - |
Free Cash Flow | 1,077 | 380.19 | 794.08 | 1,134 | 1,556 | 1,245 |
Free Cash Flow Per Share | 0.62 | 0.22 | 0.47 | 0.66 | 0.93 | 0.78 |
Dividend Per Share | 0.360 | 0.360 | 0.900 | 0.180 | 0.700 | 0.700 |
Dividend Growth | -60.00% | -60.00% | 400.00% | -74.29% | - | 94.44% |
Gross Margin | 66.32% | 66.06% | 68.76% | 68.13% | 65.76% | 62.65% |
Operating Margin | 14.49% | 10.88% | 19.63% | 19.86% | 24.18% | 22.34% |
Profit Margin | 11.49% | 9.55% | 18.56% | 17.63% | 23.60% | 25.01% |
Free Cash Flow Margin | 17.88% | 5.56% | 8.44% | 14.43% | 20.94% | 20.42% |
EBITDA | 1,089 | 964.15 | 2,072 | 1,773 | 2,012 | 1,567 |
EBITDA Margin | 18.08% | 14.10% | 22.02% | 22.55% | 27.07% | 25.70% |
D&A For EBITDA | 216.51 | 220.11 | 224.91 | 212.18 | 215.35 | 205.21 |
EBIT | 872.17 | 744.04 | 1,847 | 1,561 | 1,797 | 1,361 |
EBIT Margin | 14.49% | 10.88% | 19.63% | 19.86% | 24.18% | 22.34% |
Effective Tax Rate | 28.47% | 28.06% | 19.00% | 17.22% | 18.90% | 12.70% |
Revenue as Reported | 6,020 | 6,838 | 9,407 | 7,861 | 7,431 | 6,095 |
Advertising Expenses | - | 758.7 | 1,113 | 996.14 | 778.63 | 965.65 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.